• Rotavirus vaccines: Current status and future considerations
  • Vaccines against <i>Clostridium difficile</i>
  • Immunotherapy in allergy and cellular tests: State of art
  • Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China
  • HPV vaccine uptake after introduction of the vaccine in Germany: An analysis of administrative data
  • Knowledge and risk perception of measles and factors associated with vaccination decisions in subjects consulting university affiliated public hospitals in Lyon, France, after measles infection<br />

22 Apr 2014

Rotavirus vaccines: Current status and future considerations

Catherine Yen, Jacqueline E Tate, Terri B Hyde, Margaret M Cortese, Benjamin A Lopman, Baoming Jiang, Roger I Glass and Umesh D Parashar


17 Mar 2014

Vaccines against Clostridium difficile

Rosanna Leuzzi, Roberto Adamo and Maria Scarselli


2 May 2014

Immunotherapy in allergy and cellular tests: State of art

Salvatore Chirumbolo


14 Mar 2014

Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category II exposure in China

Quan Hu, Man-Qing Liu, Zheng-Gang Zhu, Ze-Rong Zhu and Sha Lu


17 Mar 2014

HPV vaccine uptake after introduction of the vaccine in Germany: An analysis of administrative data

Sabrina Hense, Kathrin Hillebrand, Johannes Horn, Rafael Mikolajczyk, Renate Schulze-Rath and Edeltraut Garbe

Knowledge and risk perception of measles and factors associated with vaccination decisions in subjects consulting university affiliated public hospitals in Lyon, France, after measles infection

Abdoulaye Tour, Mitra Saadatian-Elahi, Daniel Floret, Bruno Lina, Jean-Sebastien Casalegno and Philippe Vanhems

Current Issue

Human Vaccines & Immunotherapeutics

July 2014

Volume 10, Issue 7

View current issue

About the cover image
Confocal images of CHO cells treated with different PTx concentrations for 12 h, negative control. For more information see Tan et al.

Open Access

Human Vaccines & Immunotherapeutics offers a highly competitive open access fee for authors who wish for free access to and distribution of published articles. Authors retain copyright of their work by utilizing a Creative Commons attribution license. Open Access papers will be submitted to PubMed Central immediately upon final publication of each issue.

Open Access Fees

Research Papers and Reports, OA fee is $750.00 USD

Reviews, Brief Reports and Short Communications, OA fee is $500.00 USD

All other types of papers, OA fee is $250.00

Journal Description

Human Vaccines & Immunotherapeutics is a unique peer-reviewed journal, focused exclusively on vaccines and immunotherapeutics for humans.

Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can help to promote interest by keeping investigators updated as well as to enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.

Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors. Articles cover topics including but not limited to research, development, clinical, regulatory, production, epidemiology, effectiveness, health economics, use in the field, perceptions, acceptance, and safety.

Featured Special Focuses

Immunotherapy

HPV

Influenza

Special Section: NIC24

Recent Articles

Most Popular Downloads